Table 3.

Multivariate Analysis of Clinical Variables Associated with Soluble Tim-3 Plasma Levels^*

Characteristic	Effect Ratio (95% CI)	P Value
Sample characteristics
Upper-gut GVHD†	1.04 (.80 to 1.33)	.78
Mid-gut GVHD†	1.98 (1.20 to 3.29)	.008
Patient pretransplantation characteristics
CMV seropositive pretransplantation	1.32 (1.02 to 1.72)	.04
Donor CMV seropositive	1.17 (.92 to 1.50)	.21
Unrelated donor	1.35 (1.02 to 1.78)	.04
Mismatched donor	1.09 (.76 to 1.57)	.63
Age (per decade)	1.00 (.98 to 1.03)	.75
Female	.94 (.72 to 1.23)	.66
Female to male D/R	.86 (.62 to 1.20)	.37
PBSC	.93 (.56 to 1.56)	.79
TBI (>1200 cGy)	1.14 (.88 to 1.47)	.33

GVHD indicates graft-versus-host disease; CMV, cytomegalovirus; PBSC, peripheral blood stem cells; TBI, total body irradiation; D/R, donor/recipient.

^*Multivariate analysis of soluble Tim-3 plasma levels in 303 samples collected from 127 patients before initiation of treatment for acute GVHD. Data were analyzed after log transformation of Tim-3 levels. The “effect ratio” is the antilog of the estimated difference in means on the log scale, and represents a multiplicative effect of covariates on Tim-3 levels. Models were also adjusted for time since HCT (linear, quadratic, and cubic terms).

^†Defined as any sample within 15 days of onset of treatment for GVHD and compared with grade 0 to 1 acute GVHD.